Australia: Incannex plans move of shares to the US

Incannex, a clinical stage pharmaceutical development company, is planning to redomicile from Australia to the US. The firm will delist from ASX and list on Nasdaq under Incannex Healthcare, once all approvals are in place. Incannex shareholders will be given the opportunity to vote on the plan in October 2023. Listing in the US will…

You must be a HMI Subscriber to view this content.

Subscribe Now »